These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 29792354)

  • 1. Challenges with biomarkers in cancer drug discovery and development.
    Ileana Dumbrava E; Meric-Bernstam F; Yap TA
    Expert Opin Drug Discov; 2018 Aug; 13(8):685-690. PubMed ID: 29792354
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.
    Weng T; Jenkins BJ; Saad MI
    Methods Mol Biol; 2024; 2806():19-30. PubMed ID: 38676793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H
    Cancer Cell; 2024 Jun; 42(6):923-929. PubMed ID: 38861927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Development of Promising Anticancer Agents
    Carradori S
    Anticancer Agents Med Chem; 2024; 24(4):235. PubMed ID: 38745440
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.
    Maeser D; Zhang W; Huang Y; Huang RS
    Curr Opin Struct Biol; 2024 Feb; 84():102745. PubMed ID: 38109840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-demand modular assembly for expedited PROTAC development.
    Mukherjee A; Kadam VD; Miao Q; Zhang W; MacKenzie KR; Tan Z; Teng M
    Expert Opin Drug Discov; 2024 Jul; 19(7):769-772. PubMed ID: 38842359
    [No Abstract]   [Full Text] [Related]  

  • 7. Including African data in drug discovery and development.
    Veale CGL; Edkins AL; Winks S; Njoroge M; Chibale K
    Nat Rev Drug Discov; 2023 Jul; 22(7):521-522. PubMed ID: 37264173
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.
    Paul T; Palaniyandi K; Gnanasampanthapandian D
    Curr Aging Sci; 2024; 17(1):16-30. PubMed ID: 38062658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-of-1 Trials in Cancer Drug Development.
    Gouda MA; Buschhorn L; Schneeweiss A; Wahida A; Subbiah V
    Cancer Discov; 2023 Jun; 13(6):1301-1309. PubMed ID: 37070849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible Sensing Systems for Cancer Diagnostics.
    Brooks AK; Chakravarty S; Yadavalli VK
    Adv Exp Med Biol; 2022; 1379():275-306. PubMed ID: 35760996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Modelling a Key Method for Potential Therapeutic Drug Discovery.
    Karkoutly O; Dhasmana A; Dhevan V; Chauhan SC; Tripathi MK
    Biomed J Sci Tech Res; 2021 Jul; 37(3):29427-29431. PubMed ID: 35071996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity.
    de Lima Fontes M; Neves FML; Santos KS; Fusco-Almeida AM; Giannini MJSM; Felisbino SL; Deffune E; Moroz A
    Front Immunol; 2021; 12():760817. PubMed ID: 34950138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
    Parakh S; Nicolazzo J; Scott AM; Gan HK
    Front Oncol; 2021; 11():718590. PubMed ID: 34926242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.
    Lucas AT; Moody A; Schorzman AN; Zamboni WC
    Antibodies (Basel); 2021 Jul; 10(3):. PubMed ID: 34449544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.
    Kathad U; Kulkarni A; McDermott JR; Wegner J; Carr P; Biyani N; Modali R; Richard JP; Sharma P; Bhatia K
    BMC Bioinformatics; 2021 Mar; 22(1):102. PubMed ID: 33653269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
    Patel P; Alrifai D; McDonald F; Forster M;
    Br J Cancer; 2020 Dec; 123(Suppl 1):18-27. PubMed ID: 33293672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
    Maia MC; Salgia M; Pal SK
    Nat Rev Urol; 2020 May; 17(5):271-291. PubMed ID: 32203306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy gap between phase II and subsequent phase III studies in oncology.
    Vreman RA; Belitser SV; Mota ATM; Hövels AM; Goettsch WG; Roes KCB; Leufkens HGM; Mantel-Teeuwisse AK
    Br J Clin Pharmacol; 2020 Jul; 86(7):1306-1313. PubMed ID: 32034790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.
    Goos JACM; Cho A; Carter LM; Dilling TR; Davydova M; Mandleywala K; Puttick S; Gupta A; Price WS; Quinn JF; Whittaker MR; Lewis JS; Davis TP
    Theranostics; 2020; 10(2):567-584. PubMed ID: 31903138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.
    Phan N; Hong JJ; Tofig B; Mapua M; Elashoff D; Moatamed NA; Huang J; Memarzadeh S; Damoiseaux R; Soragni A
    Commun Biol; 2019; 2():78. PubMed ID: 30820473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.